Literature DB >> 16598537

[Long-standing therapy of the metabolic syndrome in diabetics after coronary artery bypass surgery].

A Steinmetz1.   

Abstract

Patients with type 2 diabetes often also exhibit additional features of the metabolic syndrome. These include specifically central obesity triggering development and maintenance of diabetes together with arterial hypertension, hypertriglyceridemia and low levels of high-density lipoprotein cholesterol. Chronic therapy of the metabolic syndrome in diabetics after coronary bypass surgery focuses on changes in lifestyle, i.e., cessation of smoking, changes in nutrition and increase in physical activity. Nutrition aims at fat reduction and modification to reduce saturated fatty acids, to allow mono- and polyunsaturated fatty acids instead, and moderate alcohol consumption. High fiber and complex carbohydrate diet complete the recommendations. Nutrition therapy connected to increases in physical activity are aimed at reducing weight in overweight and obese subjects, which should reduce their body weight by 5 to 10% within about 6 months. Normal weight subjects benefit from increases in physical activity by lipid and glucose regulation as well as by reduction in mortality.Diabetes-specific therapy aims at normoglycemia including postprandial blood glucose levels, reduces blood pressure supported by ACE inhibitors and aims at weight reduction. Reduction of LDL-cholesterol is the first line therapy, also diminishing small-dense LDL particles. Decreasing triglycerides and increasing HDL-cholesterol are further lipid-regulating aims. Specifically diabetics after coronary bypass surgery need LDL-cholesterol levels below 70 mg/d (1.8 mmol/L) and triglycerides below 150 mg/dL (1.7 mmol/L). In addition, in males HDL-cholesterol should be at least above 40 mg/dl (1 mmol/L), in females above 50 mg/dL (1.3 mmol/L).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598537     DOI: 10.1007/s00392-006-1112-1

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  20 in total

1.  Recommendations for the nutritional management of patients with diabetes mellitus.

Authors: 
Journal:  Eur J Clin Nutr       Date:  2000-04       Impact factor: 4.016

2.  Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.

Authors:  M L Wolfe; S F Vartanian; J L Ross; L L Bansavich; E R Mohler; E Meagher; C A Friedrich; D J Rader
Journal:  Am J Cardiol       Date:  2001-02-15       Impact factor: 2.778

Review 3.  Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update.

Authors:  Antonio M Gotto; Eliot A Brinton
Journal:  J Am Coll Cardiol       Date:  2004-03-03       Impact factor: 24.094

Review 4.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

5.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

6.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

Authors: 
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

7.  Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

Authors:  Paul L Canner; Curt D Furberg; Michael L Terrin; Mark E McGovern
Journal:  Am J Cardiol       Date:  2005-01-15       Impact factor: 2.778

8.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

9.  Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction.

Authors:  Chong Do Lee; Aaron R Folsom; James S Pankow; Frederick L Brancati
Journal:  Circulation       Date:  2004-02-02       Impact factor: 29.690

Review 10.  Diabetic dyslipidemia.

Authors:  R A Kreisberg
Journal:  Am J Cardiol       Date:  1998-12-17       Impact factor: 2.778

View more
  1 in total

1.  Low HDL levels and the risk of death, sepsis and malignancy.

Authors:  Renana Shor; Julio Wainstein; David Oz; Mona Boaz; Zipora Matas; Asora Fux; Aaron Halabe
Journal:  Clin Res Cardiol       Date:  2007-12-01       Impact factor: 5.460

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.